Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
This drug is selected. Its supporting articles are shown below.
…in TRED-HF received angiotensin receptor–neprilysin inhibitors (ARNIs) or SGLT2 inhibitors, compared with 61% and 63% of TRED-HF2 pat…
…und Sodium glucose co-transporter-2 inhibitors (SGLT2i) such as canagliflozin have been shown to have beneficial cardiovascular and renal eff…
… outcome (10%), and incident CKD stages 3–4 (23%) compared with glipizide. However, glyburide was associated with significantly higher ri…
…ults Of the 231 patients screened, 43 met eligibility criteria. Furosemide up titration and SGLT2i addition were the most common changes i…
…. 93% of patients were on beta blocker. 74% were on MRA, 74% on SGLT2i. 6 patients were readmitted to hospital from VW. The median NT …
…inhibitors or angiotensin receptor-neprilysin inhibitor (ARNI), beta-blockers, mineralocorticoid receptor antagonists (MRA) and sodium-glucos…
…ibitor (SGLT2i), n (%) 43 (51.8) Loop diuretic, n (%) 55 (66.3) Amiodarone, n (%) 19 (22.9) Optimised on all heart failure medications, n …
… years. The impact of novel cardiovascular therapies, including SGLT2i and GLP1 agonists, on broader long-term population data will be…
…)0.73 Diuretic 5 (17%)6 (19%)>0.99 Statin 23 (77%)25 (78%)>0.99 Biguanide 20 (67%)26 (81%)0.25 Sulphonylurea 1 (3%)1 (3%)>0.99 GLP1-RA 1 …
…ted the true neuroprotective effects of GLP-1 RAs compared with metformin. This underscores the potential superiority of GLP-1 RAs and hi…